NOVO NORDISK HEALTHCARE AG has a total of 851 patent applications. It decreased the IP activity by 22.0%. Its first patent ever was published in 1986. It filed its patents most often in EPO (European Patent Office), United States and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals, biotechnology and foods and drinks are TIANSHILI PHARM CO LTD, HALOZYME INC and BIOAXONE BIOSCIENCES INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 172 | |
#2 | United States | 168 | |
#3 | WIPO (World Intellectual Property Organization) | 90 | |
#4 | China | 88 | |
#5 | Australia | 50 | |
#6 | Canada | 39 | |
#7 | Brazil | 38 | |
#8 | Japan | 38 | |
#9 | Republic of Korea | 38 | |
#10 | Mexico | 32 | |
#11 | Israel | 23 | |
#12 | Hungary | 18 | |
#13 | Norway | 13 | |
#14 | South Africa | 13 | |
#15 | Poland | 11 | |
#16 | Taiwan | 6 | |
#17 | Ukraine | 6 | |
#18 | Czechia | 3 | |
#19 | Denmark | 2 | |
#20 | Russian Federation | 2 | |
#21 | Serbia | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Foods and drinks | |
#4 | Medical technology | |
#5 | Measurement | |
#6 | Machines |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Microorganisms | |
#4 | Enzymes | |
#5 | Peptides | |
#6 | Fermentation | |
#7 | Analysing materials | |
#8 | Medical purpose containers | |
#9 | Syringes | |
#10 | Unspecified technologies |
# | Name | Total Patents |
---|---|---|
#1 | Olsen Ole Hvilsted | 89 |
#2 | Persson Egon | 74 |
#3 | Jensen Michael Bech | 70 |
#4 | Behrens Carsten | 65 |
#5 | Rojkjaer Rasmus | 60 |
#6 | Kornfelt Troels | 56 |
#7 | Johansen Nils Langeland | 51 |
#8 | Hansen Birthe Lykkegaard | 50 |
#9 | Krarup Janus | 49 |
#10 | Andersen Henrik Sune | 34 |
Publication | Filing date | Title |
---|---|---|
WO2017009136A1 | Factor xiii for the treatment of interstitial cystitis | |
WO2016034534A1 | Lysine rich basic pre-sequences | |
EP3104892A1 | Coagulation factor ix conjugates | |
US2016303248A1 | Method for Thioether Conjugation of Proteins | |
TW201533058A | Coagulation factor VII polypeptides | |
KR20160065925A | Coagulation factor vii polypeptides | |
WO2015036553A1 | Thiol functionalized polymers | |
WO2014166836A1 | Growth hormone compound formulation | |
CN105229035A | Growth hormone compound | |
WO2014060512A1 | Fatty acid acylated amino acids for growth hormone delivery | |
WO2014060397A1 | Factor vii conjugates | |
EP2906693A1 | Coagulation factor vii polypeptides | |
EP2906236A1 | Liquid pharmaceutical composition of factor vii polypeptide | |
CN104394906A | Method of manufacturing a medical device | |
AU2013204527A1 | Growth hormones with prolonged in-vivo efficacy | |
BR112014013551A2 | medical device that has integrated sequence control | |
WO2013076129A1 | Barrier element removal | |
WO2013053949A1 | Pre-assembled fluid transfer arrangement | |
WO2013053935A1 | Sterile spike compartment | |
AU2012213951A1 | A closed container comprising an activated factor VII polypeptide, processes for the preparation of the same, and a kit and a method for use of the kit |